|
1
|
McCann S, Passweg J, Bacigalupo A,
Locasciulli A, Locatelli F, Ryan J, Schrezenmeier H and Lawler M:
The influence of cyclosporin alone, or cyclosporin and
methotrexate, on the incidence of mixed haematopoietic chimaerism
following allogeneic sibling bone marrow transplantation for severe
aplastic anaemia. Bone Marrow Transplant. 39:109–114.
2007.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Teuffel O, Schrauder A, Sykora KW,
Zimmermann M, Reiter A, Welte K and Schrappe M: The impact of
cyclosporin A on acute graft-versus-host disease after allogeneic
bone marrow transplantation in children and adolescents with acute
lymphoblastic leukemia. Bone Marrow Transplant. 36:145–150.
2005.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Bacigalupo A, Vitale V, Corvò R, Barra S,
Lamparelli T, Gualandi F, Mordini N, Berisso G, Bregante S, Raiola
AM, et al: The combined effect of total body irradiation (TBI) and
cyclosporin A (CyA) on the risk of relapse in patients with acute
myeloid leukaemia undergoing allogeneic bone marrow
transplantation. Br J Haematol. 108:99–104. 2000.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Brandenburg U, Gottlieb D and Bradstock K:
Antileukemic effects of rapid cyclosporin withdrawal in patients
with relapsed chronic myeloid leukemia after allogeneic bone marrow
transplantation. Leuk Lymphoma. 31:545–550. 1998.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Goldman JM, Apperley JF, Jones L, Marcus
R, Goolden AW, Batchelor R, Hale G, Waldmann H, Reid CD, Hows J, et
al: Bone marrow transplantation for patients with chronic myeloid
leukemia. N Engl J Med. 314:202–207. 1986.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Kohno A, Morishita Y, Iida H, Sakamaki H,
Yokozawa T, Kitaori K, Ozeki K, Matsuo K and Sao H: Low-dose
cyclosporin A with short-term methotrexate for graft-versus-host
disease prophylaxis in allogeneic bone marrow transplantation from
human leukocyte antigen-identical siblings: A prospective phase II
study in Japanese patients. Int J Hematol. 84:83–89.
2006.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Rowlings PA, Przepiorka D, Klein JP, Gale
RP, Passweg JR, Henslee-Downey PJ, Cahn JY, Calderwood S, Gratwohl
A, Socie G, et al: IBMTR Severity Index for grading acute
graft-versus-host disease: Retrospective comparison with Glucksberg
grade. Br J Haematol. 97:855–864. 1997.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Martin PJ, Schoch G, Fisher L, Byers V,
Anasetti C, Appelbaum FR, Beatty PG, Doney K, McDonald GB, Sanders
JE, et al: A retrospective analysis of therapy for acute
graft-versus-host disease: Initial treatment. Blood. 76:1464–1472.
1990.PubMed/NCBI
|
|
9
|
Martin PJ, Schoch G, Fisher L, Byers V,
Appelbaum FR, McDonald GB, Storb R and Hansen JA: A retrospective
analysis of therapy for acute graft-versus-host disease: Secondary
treatment. Blood. 77:1821–1828. 1991.PubMed/NCBI
|
|
10
|
Ferrara JL, Levine JE, Reddy P and Holler
E: Graft-versus-host disease. Lancet. 373:1550–1561.
2009.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Hill GR and Ferrara JL: The primacy of the
gastrointestinal tract as a target organ of acute graft-versus-host
disease: Rationale for the use of cytokine shields in allogeneic
bone marrow transplantation. Blood. 95:2754–2759. 2000.PubMed/NCBI
|
|
12
|
Fowler DH, Foley J, Whit-Shan Hou J, Odom
J, Castro K, Steinberg SM, Gea-Banacloche J, Kasten-Sportes C,
Gress RE and Bishop MR: Clinical ‘cytokine storm’ as revealed by
monocyte intracellular flow cytometry: Correlation of tumor
necrosis factor alpha with severe gut graft-versus-host disease.
Clin Gastroenterol Hepatol. 2:237–245. 2004.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Gérard C, Bleyzac N, Girard P, Freyer G,
Bertrand Y and Tod M: Links between cyclosporin exposure in tissues
and graft-versus-host disease in pediatric bone marrow
transplantation: Analysis by a PBPK model. Pharm Res. 28:531–539.
2011.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Kobayashi R, Yabe H, Hara J, Morimoto A,
Tsuchida M, Mugishima H, Ohara A, Tsukimoto I, Kato K, Kigasawa H,
et al: Preceding immunosuppressive therapy with antithymocyte
globulin and ciclosporin increases the incidence of graft rejection
in children with aplastic anaemia who underwent allogeneic bone
marrow transplantation from HLA-identical siblings. Br J Haematol.
135:693–696. 2006.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Bowers LD: Therapeutic monitoring for
cyclosporine: Difficulties in establishing a therapeutic window.
Clin Biochem. 24:81–87. 1991.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Wang DD, Ye QF, Chen X, Xu H and Li ZP:
Population pharmacokinetics and initial dosing regimen optimization
of cyclosporin in pediatric hemophagocytic lymphohistiocytosis
patients. Xenobiotica. 50:435–441. 2020.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Li TF, Hu L, Ma XL, Huang L, Liu XM, Luo
XX, Feng WY and Wu CF: Population pharmacokinetics of cyclosporine
in Chinese children receiving hematopoietic stem cell
transplantation. Acta Pharmacol Sin. 40:1603–1610. 2019.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Liu YO, Jia B, Chen CY, Zhou Y, Cui YM and
Zhou FD: Population pharmacokinetics of cyclosporine A in Chinese
patients with nephrotic syndrome in individualized drug
administration. Int J Clin Pharmacol Ther. 58:1–9. 2020.PubMed/NCBI View
Article : Google Scholar
|
|
19
|
Martin P, Bleyzac N, Souillet G, Galambrun
C, Bertrand Y, Maire PH, Jelliffe RW and Aulagner G: Relationship
between CsA trough blood concentration and severity of acute
graft-versus-host disease after paediatric stem cell
transplantation from matched-sibling or unrelated donors. Bone
Marrow Transplant. 32:777–784. 2003.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Carlens S, Aschan J, Remberger M, Dilber M
and Ringden O: Low-dose cyclosporine of short duration increases
the risk of mild and moderate GVHD and reduces the risk of relapse
in HLA-identical sibling marrow transplant recipients with
leukaemia. Bone Marrow Transplant. 24:629–635. 1999.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Ni SQ, Zhao W, Wang J, Zeng S, Chen SQ,
Jacqz-Aigrain E and Zhao ZY: Population pharmacokinetics of
ciclosporin in Chinese children with aplastic anemia: Effects of
weight, renal function and stanozolol administration. Acta
Pharmacol Sin. 34:969–975. 2013.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Fanta S, Jonsson S, Backman JT, Karlsson
MO and Hoppu K: Developmental pharmacokinetics of ciclosporin-a
population pharmacokinetic study in paediatric renal transplant
candidates. Br J Clin Pharmacol. 64:772–784. 2007.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Irtan S, Saint-Marcoux F, Rousseau A,
Zhang D, Leroy V, Marquet P and Jacqz-Aigrain E: Population
pharmacokinetics and bayesian estimator of cyclosporine in
pediatric renal transplant patients. Ther Drug Monit. 29:96–102.
2007.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Wilhelm AJ, de Graaf P, Veldkamp AI,
Janssen JJ, Huijgens PC and Swart EL: Population pharmacokinetics
of ciclosporin in haematopoietic allogeneic stem cell
transplantation with emphasis on limited sampling strategy. Br J
Clin Pharmacol. 73:553–563. 2012.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Wang D, Chen X and Li Z: Cyclosporin
population pharmacokinetics in pediatric refractory nephrotic
syndrome based on real-world studies: Effects of body weight and
spirolactone administration. Exp Ther Med. 17:3015–3020.
2019.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Anderson BJ and Holford NH:
Mechanism-based concepts of size and maturity in pharmacokinetics.
Annu Rev Pharmacol Toxicol. 48:303–332. 2008.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Willemze AJ, Cremers SC, Schoemaker RC,
Lankester AC, den Hartigh J, Burggraaf J and Vossen JM: Ciclosporin
kinetics in children after stem cell transplantation. Br J Clin
Pharmacol. 66:539–545. 2008.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Weiss M, Steinbach D, Zintl F, Beck J and
Gruhn B: Superior outcome using cyclosporin A alone versus
cyclosporin A plus methotrexate for post-transplant
immunosuppression in children with acute leukemia undergoing
sibling hematopoietic stem cell transplantation. J Cancer Res Clin
Oncol. 141:1089–1094. 2015.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Choi JS, Lee SH, Chung SJ, Yoo KH, Sung KW
and Koo HH: Assessment of converting from intravenous to oral
administration of cyclosporin A in pediatric allogeneic
hematopoietic stem cell transplant recipients. Bone Marrow
Transplant. 38:29–35. 2006.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Muduma G, Saunders R, Odeyemi I and
Pollock RF: Systematic review and meta-analysis of tacrolimus
versus ciclosporin as primary immunosuppression after liver
transplant. PLoS One. 11(e0160421)2016.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Muduma G, Odeyemi I and Pollock RF: A
cost-utility analysis of prolonged-release tacrolimus relative to
immediate-release tacrolimus and ciclosporin in liver transplant
recipients in the UK. J Med Econ. 19:995–1002. 2016.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Riegersperger M, Plischke M,
Jallitsch-Halper A, Steinhauser C, Födinger M, Winkelmayer WC,
Dunkler D and Sunder-Plassmann G: A non-randomized trial of
conversion from ciclosporin and tacrolimus to tacrolimus MR4 in
stable long-term kidney transplant recipients: Graft function and
influences of ABCB1 genotypes. PLoS One.
14(e0218709)2019.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Gathogo E, Harber M, Bhagani S, Levy J,
Jones R, Hilton R, Davies G and Post FA: UK HIV Kidney
Transplantation Study Group. Impact of tacrolimus compared with
cyclosporin on the incidence of acute allograft rejection in human
immunodeficiency virus-positive kidney transplant recipients.
Transplantation. 100:871–878. 2016.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Penninga L, Penninga EI, Møller CH,
Iversen M, Steinbrüchel DA and Gluud C: Tacrolimus versus
cyclosporin as primary immunosuppression for lung transplant
recipients. Cochrane Database Syst Rev: CD008817, 2013.
|
|
35
|
Jia Y, Meng X, Li Y, Xu C, Zeng W, Jiao Y
and Han W: Optimal sampling time-point for cyclosporin A
concentration monitoring in heart transplant recipients. Exp Ther
Med. 16:4265–4270. 2018.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Robertsen I, Falck P, Andreassen AK, Naess
NK, Lunder N, Christensen H, Gullestad L and Asberg A:
Endomyocardial, intralymphocyte, and whole blood concentrations of
ciclosporin A in heart transplant recipients. Transplant Res.
2(5)2013.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Rosmarin DM, Lebwohl M, Elewski BE and
Gottlieb AB: National Psoriasis Foundation. Cyclosporine and
psoriasis: 2008 National Psoriasis Foundation Consensus Conference.
J Am Acad Dermatol. 62:838–853. 2010.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Gupta AK, Ellis CN, Cooper KD, Nickoloff
BJ, Ho VC, Chan LS, Hamilton TA, Tellner DC, Griffiths CE and
Voorhees JJ: Oral cyclosporine for the treatment of alopecia
areata. A clinical and immunohistochemical analysis. J Am Acad
Dermatol. 22:242–250. 1990.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Boubouka CD, Charissi C, Kouimintzis D,
Kalogeromitros D, Stavropoulos PG and Katsarou A: Treatment of
autoimmune urticaria with low-dose cyclosporin A: A one-year
follow-up. Acta Derm Venereol. 91:50–54. 2011.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Ahronowitz I, Harp J and Shinkai K:
Etiology and management of pyoderma gangrenosum: A comprehensive
review. Am J Clin Dermatol. 13:191–211. 2012.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Berth-Jones J, Finlay AY, Zaki I, Tan B,
Goodyear H, Lewis-Jones S, Cork MJ, Bleehen SS, Salek MS, Allen BR,
et al: Cyclosporine in severe childhood atopic dermatitis: A
multicenter study. J Am Acad Dermatol. 34:1016–1021.
1996.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Zavada J, Pesickova S, Rysava R, Olejarova
M, Horák P, Hrncír Z, Rychlík I, Havrda M, Vítova J, Lukác J, et
al: Cyclosporine A or intravenous cyclophosphamide for lupus
nephritis: The Cyclofa-Lune study. Lupus. 19:1281–1289.
2010.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Zheng Y, Liu Y and Chu Y:
Immunosuppressive therapy for acquired severe aplastic anemia
(SAA): A prospective comparison of four different regimens. Exp
Hematol. 34:826–831. 2006.PubMed/NCBI View Article : Google Scholar
|
|
44
|
McDonald JW, Feagan BG, Jewell D, Brynskov
J, Stange EF and Macdonald JK: Cyclosporine for induction of
remission in Crohn's disease. Cochrane Database Syst Rev: CD000297,
2005.
|
|
45
|
Meier J and Sturm A: Current treatment of
ulcerative colitis. World J Gastroenterol. 17:3204–3212.
2011.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Paziana K, Del Monaco M, Cardonick E,
Moritz M, Keller M, Smith B, Coscia L and Armenti V: Ciclosporin
use during pregnancy. Drug Saf. 36:279–294. 2013.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Barr WH: Cyclosporine: The case for
expanding bioequivalence criteria to include measures of individual
bioequivalence in relevant population subsets. Transplant Proc.
31:25S–30S. 1999.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Kahan BD, Welsh M and Rutzky LP:
Challenges in cyclosporine therapy: The role of therapeutic
monitoring by area under the curve monitoring. Ther Drug Monit.
17:621–624. 1995.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Colaizzi JL and Lowenthal DT: Critical
therapeutic categories: A contraindication to generic substitution?
Clin Ther. 8:370–379. 1986.PubMed/NCBI
|
|
50
|
Zheng QS and Li LJ: Pharmacometrics: A
quantitative tool of pharmacological research. Acta Pharmacol Sin.
33:1337–1338. 2012.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Lu T, Zhu X, Xu S, Zhao M, Huang X, Wang Z
and Zhao L: Dosage optimization based on population pharmacokinetic
analysis of tacrolimus in Chinese patients with nephrotic syndrome.
Pharm Res. 36(45)2019.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Wang X, Han Y, Chen C, Ma L, Xiao H, Zhou
Y, Cui Y, Wang F, Su B, Yao Y, et al: Population pharmacokinetics
and dosage optimization of tacrolimus in pediatric patients with
nephrotic syndrome. Int J Clin Pharmacol Ther. 57:125–134.
2019.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Chen CY, Zhou Y, Cui YM, Yang T, Zhao X
and Wu Y: Population pharmacokinetics and dose simulation of
oxcarbazepine in Chinese paediatric patients with epilepsy. J Clin
Pharm Ther. 44:300–311. 2019.PubMed/NCBI View Article : Google Scholar
|
|
54
|
Zheng Y, Liu SP, Xu BP, Shi ZR, Wang K,
Yang JB, Huang X, Tang BH, Chen XK, Shi HY, et al: Population
pharmacokinetics and dosing optimization of azithromycin in
children with community-acquired pneumonia. Antimicrob Agents
Chemother. 62:e00686–18. 2018.PubMed/NCBI View Article : Google Scholar
|
|
55
|
Chen Y, Wu D, Dong M, Zhu Y, Lu J, Li X,
Chen C and Li Z: Population pharmacokinetics of vancomycin and
AUC-guided dosing in Chinese neonates and young infants. Eur J Clin
Pharmacol. 74:921–930. 2018.PubMed/NCBI View Article : Google Scholar
|
|
56
|
Anderson BJ and Holford NH: Tips and traps
analyzing pediatric PK data. Paediatr Anaesth. 21:222–237.
2011.PubMed/NCBI View Article : Google Scholar
|
|
57
|
Holford NH: A size standard for
pharmacokinetics. Clin Pharmacokinet. 30:329–332. 1996.PubMed/NCBI View Article : Google Scholar
|
|
58
|
Hao GX, Huang X, Zhang DF, Zheng Y, Shi
HY, Li Y, Jacqz-Aigrain E and Zhao W: Population pharmacokinetics
of tacrolimus in children with nephrotic syndrome. Br J Clin
Pharmacol. 84:1748–1756. 2018.PubMed/NCBI View Article : Google Scholar
|
|
59
|
Wang DD, Chen X and Li ZP: Wuzhi capsule
and haemoglobin influence tacrolimus elimination in paediatric
kidney transplantation patients in a population pharmacokinetics
analysis: A retrospective study. J Clin Pharm Ther. 44:611–617.
2019.PubMed/NCBI View Article : Google Scholar
|
|
60
|
Wang DD, Chen X, Fu M, Zheng QS, Xu H and
Li ZP: Model extrapolation to a real-world dataset: Evaluation of
tacrolimus population pharmacokinetics and drug interaction in
pediatric liver transplantation patients. Xenobiotica. 50:371–379.
2020.PubMed/NCBI View Article : Google Scholar
|
